SAGIT for Classification of Patients With Acromegaly in Clinical Practice
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Endocrine |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/16/2019 |
| Start Date: | February 2013 |
| End Date: | May 2014 |
Testing the Use of SAGIT for Classification of Patients With Acromegaly in Clinical Practice
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated
comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported
Outcomes (ClinROs) tool developed to describe patients with acromegaly. This study will
determine the potential use of a finalised operational version for patient classification in
clinical practice and studies.
In addition, this study intends to carry out a qualitative evaluation of the acceptability of
SAGIT by the practicing endocrinologist in terms of relevance, ease of use, applicability and
usefulness of the tool in practice.
comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported
Outcomes (ClinROs) tool developed to describe patients with acromegaly. This study will
determine the potential use of a finalised operational version for patient classification in
clinical practice and studies.
In addition, this study intends to carry out a qualitative evaluation of the acceptability of
SAGIT by the practicing endocrinologist in terms of relevance, ease of use, applicability and
usefulness of the tool in practice.
Inclusion Criteria:
- Male or female aged 18 years-old or above
- Patient with diagnosis of acromegaly with the presence of pituitary adenoma, elevated
IGF-1 and lack of serum GH suppression after oral glucose tolerance test (OGTT)
- Controlled/stable, active and treatment naïve patients.
- Patient with the cognitive and linguistic capacities to understand the information
letter of the study
- Patient who signed informed consent
Exclusion Criteria:
- History of non-compliance or inability to reliably receive treatment in the
foreseeable future
- Gaps in treatment of greater than 1 month within the 12 months prior to study entry
We found this trial at
3
sites
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials